# YOLOv11-MFF: A multi-scale frequency-adaptive fusion network for enhanced CXR anomaly detection

## TL;DR

This paper introduces YOLOv11-MFF, a new network for detecting anomalies in chest X-rays that improves detection accuracy by adapting to lesion characteristics.

## Contribution

The novel Frequency-Adaptive Hybrid Gate and Multi Scale Parallel Large Convolution block enhance lesion detection in chest X-rays.

## Key findings

- YOLOv11-MFF achieves a precision of 48.2% and recall of 42.5% on the VinDr-CXR dataset.
- The model outperforms state-of-the-art models with an mAP@0.5 of 41.5% and mAP@0.5:0.95 of 22.6%.

## Abstract

Chest X-ray (CXR) represents one of the most widely utilized clinical diagnostic tools for thoracic diseases. Nevertheless, computer-aided diagnosis based on chest radiographs still faces considerable challenges in anomaly detection. Certain lesions in CXRs exhibit subtle radiographic characteristics with ambiguous boundaries, low pixel occupancy, and weak contrast. While existing studies primarily focus on improving multi-scale feature fusion, they frequently overlook complications arising from background noise and varied lesion morphology. This study introduces YOLOv11-MFF, an enhanced YOLOv11 network with three key innovations. Specifically, a novel Frequency-Adaptive Hybrid Gate (FAHG) is developed to improve contrast differentiation between lesions and background. A Multi Scale Parallel Large Convolution (MSPLC) block is designed and integrated with the original C3k2 module to expand receptive fields and enhance long-range modeling capacity. Furthermore, a Feature Fusion module (FF) is introduced to reinforce target-relevant feature representation through channel-wise modulation via weight recalibration mechanisms. Benefiting from these advancements, the network achieves significant improvements in detecting multi-scale and overlapping lesions. Experimental results on the public VinDr-CXR dataset demonstrate that YOLOv11-MFF outperforms state-of-the-art models, achieving a precision of 48.2%, recall of 42.5%, mAP@0.5 of 41.5%, and mAP@0.5:0.95 of 22.6%.